DNA X, Inc. (SONM) raises $2.5M and targets Nasdaq equity rule compliance
Rhea-AI Filing Summary
DNA X, Inc. reported that on August 7, 2026 it sold and issued the remaining 416,667 shares of Series B Preferred Stock under its Purchase Agreement, receiving $2.5 million in cash. The company presented a pro forma view showing estimated ending stockholders’ equity of $5,840,000 as of that date.
Based on this pro forma equity, the company believes it now exceeds the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1) and is awaiting Nasdaq’s formal determination. Management notes the pro forma figures are unaudited, based on current estimates and assumptions, and for illustrative purposes only.
Positive
- Completion of the preferred stock financing added $2.5 million in cash proceeds and contributed to an estimated $5.84 million pro forma stockholders’ equity as of August 7, 2026.
- Management believes stockholders’ equity now exceeds Nasdaq’s $2.5 million requirement under Listing Rule 5550(b)(1), potentially supporting continued listing on The Nasdaq Capital Market once formally confirmed.
Negative
- None.
Filing Explained
The filing shows the pro forma equity bridge: estimated stockholders’ equity was negative 1,516 in thousands for Q2 2026 and 5,840 in thousands on August 7. The August 7 estimate includes 4,946 in thousands of financing and 3,049 in thousands from note conversion, so the reported equity improvement is an unaudited, assumption-based pro forma measure rather than a finalized balance-sheet figure.
8-K Event Classification
2 items: 3.02, 8.01
2 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Series B Preferred Stock sold: 416,667 shares
Cash proceeds from preferred stock: $2.5 million
Pro forma ending stockholders’ equity: $5,840,000
+5 more
8 metrics
Series B Preferred Stock sold
416,667 shares
Remaining shares issued on August 7, 2026 under the Purchase Agreement
Cash proceeds from preferred stock
$2.5 million
Consideration received for 416,667 Series B Preferred shares on August 7, 2026
Pro forma ending stockholders’ equity
$5,840,000
Estimated stockholders’ equity as of August 7, 2026, in thousands table
Nasdaq equity requirement
$2.5 million
Stockholders’ equity threshold under Listing Rule 5550(b)(1)
Q1 2026 net income (loss)
$6,340,000
Net income (loss) line in projected stockholders’ equity table
Q2 2026 net income (loss) (est.)
$(1,530,000)
Estimated net income (loss) for Q2 2026 in thousands table
Beginning equity Q1 2026
$(7,955,000)
Beginning stockholders’ equity for Q1 2026 in thousands table
Beginning equity Q2 2026 (est.)
$(983,000)
Beginning stockholders’ equity for Q2 2026 in thousands table
Key Terms
Series B Preferred Stock, Purchase Agreement, stockholders’ equity, Nasdaq Capital Market, +2 more
6 terms
Series B Preferred Stock financial
"sold and issued the remaining 416,667 shares of Series B Preferred Stock purchasable"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Purchase Agreement financial
"purchasable pursuant to the Purchase Agreement in exchange for cash proceeds"
A purchase agreement is a legally binding contract that spells out exactly what is being bought, for how much, and under what conditions, including timelines, seller and buyer promises, and protections if things go wrong. For investors it matters because the agreement fixes the deal’s price, risks and closing conditions—like a detailed receipt and return policy for a large transaction—so it helps determine whether the deal will complete and how it will affect the company’s value and cash flow.
stockholders’ equity financial
"believes it has stockholders’ equity in excess of the $2.5 million stockholders’ equity requirement"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
Nasdaq Capital Market regulatory
"requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule 5550(b)(1)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Listing Rule 5550(b)(1) regulatory
"requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule 5550(b)(1)"
Listing Rule 5550(b)(1) is a Nasdaq listing standard that sets a minimum share price requirement companies must meet to stay listed on the exchange. It matters to investors because falling below that threshold can trigger delisting procedures, which often reduce a stock’s visibility, trading liquidity and value; think of it like a minimum score needed to remain in a sports league — miss it and you risk being dropped until you improve.
pro forma financial
"summary pro forma presentation of stockholders’ equity giving effect to the completed transactions"
Pro forma refers to financial information that is prepared based on estimates or adjustments to show what a company's results might look like under certain scenarios, such as new projects or acquisitions. It helps investors understand the potential impact of future events by providing a clear, hypothetical view of financial performance, much like a weather forecast shows possible future conditions.
FAQ
What transaction did DNA X, Inc. (SONM) complete on August 7, 2026?
DNA X, Inc. completed the sale and issuance of the remaining 416,667 shares of Series B Preferred Stock, raising $2.5 million in cash proceeds under its Purchase Agreement.
How did the August 7, 2026 financing affect SONM’s stockholders’ equity?
After giving effect to the August 7, 2026 transactions, DNA X, Inc. estimates pro forma stockholders’ equity of $5.84 million, compared with a previously negative equity balance earlier in 2026.
Is DNA X, Inc. (SONM) now in compliance with Nasdaq’s equity rule?
The company believes its pro forma equity now exceeds Nasdaq’s $2.5 million stockholders’ equity requirement under Listing Rule 5550(b)(1) and is awaiting Nasdaq’s formal compliance determination.
What stockholders’ equity figures did SONM disclose for 2026?
DNA X, Inc. reported ending stockholders’ equity of $(983,000) for Q1 2026, $(1,516,000) for Q2 2026 (estimated), and $5,840,000 pro forma as of August 7, 2026.
What recent net income or loss figures did DNA X, Inc. (SONM) provide?
The company showed net income (loss) of $6,340,000 for Q1 2026, an estimated $(1,530,000) for Q2 2026, and an estimated $(639,000) through August 7, 2026 in its pro forma table.
AI-generated analysis. How Rhea-AI works. Not financial advice.
